EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants

Ashley C Beavis iD, Zhuo Li, Kelsey Briggs, María Cristina Gingerich, Elizabeth R Wrobel, Maria Najera, Dong An, Nichole Orr-Burks iD, Jackelyn Murray, Preetish Patil, Jiachen Huang, Jarrod Mousa iD und 9 weitere

Journal of Virology · 2025

DOI: 10.1128/jvi.01989-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Ashley C Beavis und 20 weiteren Autor:innen. Beteiligte Einrichtung: CyanVac LLC, Athens, Georgia, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Vaccines, COVID-19, Parainfluenza Virus 5. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunization with COVID-19 vaccines has greatly reduced COVID-19-related deaths and hospitalizations from SARS-CoV-2 infection, but waning immunity and the emergence of variants capable of immune escape indicate the need for annual vaccine updates or development of different SARS-CoV-2 vaccine platforms. Parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine with the ancestral spike (S) protein (CVXGA1) has been shown to be a promising next-generation COVID-19 vaccine preclinically and is currently being evaluated in humans. This work investigates the immunogenicity and efficacy of CVXGA1 and other PIV5-vectored vaccine candidates expressing additional SARS-CoV-2 nucleoprotein (N) antigen or SARS-CoV-2 variant S proteins of beta, delta, gamma, and omicron variants against homologous and heterologous challenges in hamsters. A single intranasal dose of CVXGA1 induces neutralizing antibodies (nAbs) against SARS-CoV-2 WA1 (ancestral), delta variant, and omicron variant and protects against both homologous and heterologous virus challenges. Compared to mRNA COVID-19 vaccine, neutralizing antibody titers induced by CVXGA1 were well maintained over time. When administered as a booster following two doses of an mRNA COVID-19 vaccine, PIV5-vectored vaccines expressing the S protein from WA1 (CVXGA1), delta, or omicron variants generate higher levels of cross-reactive nAbs than three doses of mRNA vaccine. Our data indicate that an intranasal PIV5-vectored COVID-19 vaccine can serve as a booster vaccine against emerging variants. IMPORTANCE With emerging new variants of concern (VOC), SARS-CoV-2 continues to be a major threat to human health. Approved COVID-19 vaccines have been less effective against these emerging VOCs. This work demonstrates the protective efficacy and strong boosting effect of an intranasal viral-vectored vaccine against SARS-CoV-2 variants in hamsters. Our intranasal vaccine can act as an effective booster for individuals already 58 vaccinated against SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19 VaccinesCOVID-19Parainfluenza Virus 5AnimalsAdministration, IntranasalSpike Glycoprotein, CoronavirusAntibodies, ViralAntibodies, NeutralizingImmunization, SecondaryCricetinaeMesocricetusHumansGenetic VectorsFemale

Stichwörter der Autor:innen

SARS-CoV-2golden Syrian hamsterparainfluenza virus 5 (PIV5)viral-vectored vaccine

Substanzen

COVID-19 VaccinesSpike Glycoprotein, CoronavirusAntibodies, ViralAntibodies, Neutralizingspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • CyanVac LLC, Athens, Georgia, USA.
  • Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
  • Department of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, Washington, USA.
  • Animal Resources, University of Georgia, Athens, Georgia, USA.
  • Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.

ORCID-Profile: Ashley C Beavis, Nichole Orr-Burks, Jarrod Mousa, Michael Gale, S Mark Tompkins, Biao He

Förderung

  • NIAID NIH HHS

Zitieren

APA

Beavis, A. C., Li, Z., Briggs, K., Gingerich, M. C., Wrobel, E. R., Najera, M., An, D., Orr-Burks, N., Murray, J., Patil, P., Huang, J., Mousa, J., Hao, L., Hsiang, T. Y., Gale, M., Harvey, S. B., Tompkins, S. M., Hogan, R. J., Lafontaine, E. R., …, & He, B. (2025). Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants. Journal of Virology. https://doi.org/10.1128/jvi.01989-24

Vancouver

Beavis AC, Li Z, Briggs K, Gingerich MC, Wrobel ER, Najera M, et al. Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants. Journal of Virology. 2025. doi:10.1128/jvi.01989-24

BibTeX
@article{Beavis2025,
  author = {Beavis, Ashley C and Li, Zhuo and Briggs, Kelsey and Gingerich, María Cristina and Wrobel, Elizabeth R and Najera, Maria and An, Dong and Orr-Burks, Nichole and Murray, Jackelyn and Patil, Preetish and Huang, Jiachen and Mousa, Jarrod and Hao, Linhui and Hsiang, Tien-Ying and Gale, Michael and Harvey, Stephen B and Tompkins, S Mark and Hogan, Robert Jeffrey and Lafontaine, Eric R and Jin, Hong and He, Biao},
  title = {Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01989-24}
}
Kostenlos starten →